Lung cancer is the leading cause of cancer-related death in men and women in the United
States, accounting for approximately 28% of total cancer deaths in 2010 despite comprising …

The development of a simple and fast cancer detection method is crucial since early
diagnosis is a key factor in increasing survival rates for lung cancer patients. Among several …

The effectual clinical benefits of immune checkpoint inhibitor (ICI) are hampered by a high
rate of innate resistance, and VEGFA may contribute to ICI treatment resistance. In this study …

Background There is a medical need for diagnostic biomarkers in lung cancer. We
evaluated the diagnostic performance of complement activation fragments. Methods We …

Colorectal cancer (CRC) is the third most common cancer worldwide and accounts for 10%
of all new cancer diagnoses. Angiogenesis is a tightly regulated process that is mediated by …

Although lung cancer remains the leading cancer killer in the United States, recently a
number of developments indicate future clinical benefit. These include evidence that …

Despite major advances in cancer therapeutics, the prognosis for lung cancer patients is still
poor and the median survival for patients presenting with advanced non-small cell lung …

Introduction Proteins are molecules that have role in the progression of the diseases.
Proteomics is a tool that can play an effective role in identifying diagnostic and therapeutic …

Background: The prognostic/predictive value of potential vascular endothelial growth factor
(VEGF) signalling biomarkers was evaluated retrospectively using samples from two …

Vascular endothelial growth factor A (VEGFA) is one of the main mediators of angiogenesis
in non‐small cell lung cancer (NSCLC). Recently, it has been described an autocrine feed …